Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 33,00 € Taxes included to order
    Pages Iconography Videos Other
    7 1 0 0


Archives of cardiovascular diseases
Volume 112, n° 3
pages 180-186 (mars 2019)
Doi : 10.1016/j.acvd.2018.11.006
Received : 5 June 2018 ;  accepted : 4 November 2018
Cliical research

Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention
 

Lee S. Nguyen, Vincent Spagnoli, Mathieu Kerneis, Marie Hauguel-Moreau, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot, Johanne Silvain , 1
 Sorbonne université , ACTION Study group , Institut de Cardiologie (APHP), INSERM UMRS 1166 , hôpital Pitié-Salpêtrière, 75013 Paris, France 

Auteur correspondant.
Summary
Background

Two biomarkers of early acute kidney injuryplasmatic neutrophil gelatinase-associated lipocalin (NGAL) and cystatin Care not used in routine clinical practice in patients with ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI) because of a lack of supporting data.

Aims

To evaluate the predictive value of NGAL and cystatin C regarding the incidence of contrast-induced acute kidney injury (CI-AKI) and clinical outcomes after STEMI in patients treated by primary PCI.

Methods

Plasmatic NGAL and cystatin C were measured on admission, before any contrast exposure, in 701 unselected patients with STEMI. Associations between biomarker concentrations and incidence of CI-AKI (assessed at 48h), haemodialysis requirement at 1 year and all-cause mortality at 1 year were assessed by logistic regression analyses and receiver operating characteristic area under the curve analysis (c -statistic). Discrimination performance comparison was performed using the DeLong test.

Results

NGAL and cystatin C had mild discrimination regarding CI-AKI, with c-statistics of 0.60 (P =0.001) and 0.60 (P =0.002), respectively. Combining NGAL and cystatin C did not improve their discrimination (c -statistic 0.61; P =0.001). There was no significant difference in discrimination between NGAL, cystatin C and baseline creatinine (P =0.57). Regression analyses showed no independent association between NGAL and CI-AKI, haemodialysis or 1-year mortality. Similarly, cystatin C was not associated with these clinical outcomes.

Conclusions

In this cohort of patients with STEMI treated by primary PCI, plasmatic NGAL and cystatin C did not provide additional value regarding CI-AKI prediction compared with known risk factors such as baseline creatinine.

The full text of this article is available in PDF format.

Keywords : STEMI, Primary PCI, Acute kidney injury, Biomarkers, Contrast volume

Abbreviations : AKIN, AMI, CI-AKI, eGFR, ELISA, NGAL, PCI, STEMI, TIMI


1  www.action-coeur.org.


© 2018  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline